[HTML][HTML] Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
Lung cancer is the second most common cause of morbidity and mortality among cancer
types worldwide, with non-small cell lung cancer (NSCLC) representing the majority of most …
types worldwide, with non-small cell lung cancer (NSCLC) representing the majority of most …
[HTML][HTML] Comprehensive analysis of histone methylation modification regulators for predicting prognosis and drug sensitivity in lung adenocarcinoma
Y Ye, L Li, Q Dai, Y Liu, L Shen - Frontiers in Cell and Developmental …, 2022 - frontiersin.org
Histone methylation is an epigenetic modification regulated by histone methyltransferases,
histone demethylases, and histone methylation reader proteins that play important roles in …
histone demethylases, and histone methylation reader proteins that play important roles in …
[PDF][PDF] Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - Heliyon, 2023 - cell.com
Introduction Although third-generation epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
Expert consensus on treatment for stage III non‐small cell lung cancer
Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high
heterogeneity. Such patients should actively receive comprehensive treatments. It is …
heterogeneity. Such patients should actively receive comprehensive treatments. It is …
STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy
Y Wang, H Qi, T Wang, W Zhang, X Shi… - Journal of …, 2024 - Taylor & Francis
A total of 162 non-small cell lung cancer (NSCLC) patients were divided into discovery (N=
68) and validation (N= 94) groups. Nine Janus kinase/Signal transducer and activator of …
68) and validation (N= 94) groups. Nine Janus kinase/Signal transducer and activator of …
[HTML][HTML] Synergistic markers based on inter-covariate association estimate treatment option with lower propensity to covariates
LWC Chan, A Sihoe - Annals of Translational Medicine, 2023 - ncbi.nlm.nih.gov
Background Propensity constitutes a common problem in identifying clinical outcome
prediction model whose covariates include the treatment option, which is assumed to be …
prediction model whose covariates include the treatment option, which is assumed to be …
埃克替尼与吉非替尼治疗EGFR 突变型晚期肺腺癌的临床疗效比较.
巫丽丽， 朱莹丽， 卓小露， 黄莉捺… - Chinese Journal of …, 2022 - search.ebscohost.com
Objective To compare the clinical efficacy, adverse events, and immunological function
status after medication of icotinib and gefitinib in the treatment of advanced lung …
status after medication of icotinib and gefitinib in the treatment of advanced lung …
[HTML][HTML] 真实世界中表皮生长因子受体酪氨酸激酶抑制剂(吉非替尼或埃克替尼) 在非小细胞肺癌患者术后辅助治疗中的临床疗效分析
王化锋， 艾江山， 胡世宇 - Advances in Clinical Medicine, 2022 - hanspub.org
目的: 探讨接受第一代表皮生长因子受体酪氨酸激酶抑制剂(吉非替尼或埃克替尼)
作为术后辅助治疗的非小细胞肺癌患者的预后以及影响预后的因素. 方法: 纳入2015-4 …
作为术后辅助治疗的非小细胞肺癌患者的预后以及影响预后的因素. 方法: 纳入2015-4 …
Oral Anticancer Therapies
A Saeed, L Hussain, H Naranmandura… - Cancer Targeting … - taylorfrancis.com
Cancer is a common and diverse disease that has been studied for decades. Some tumors
have rapid growth while some tumors progress slowly. Researchers have identified different …
have rapid growth while some tumors progress slowly. Researchers have identified different …